(Q37176562)

18 August 2017

1 reference

title

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients (English)

1 reference

18 August 2017

1 reference

1 reference

B L Kasiske

1

1 reference

18 August 2017

A de Mattos

2

1 reference

18 August 2017

S M Flechner

3

1 reference

18 August 2017

L Gallon

4

1 reference

18 August 2017

H-U Meier-Kriesche

5

1 reference

18 August 2017

M R Weir

6

1 reference

18 August 2017

A Wilkinson

7

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

American Journal of Transplantation

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

1384-1392

1 reference

18 August 2017

7

1 reference

Predicting coronary heart disease in renal transplant recipients: a prospective study.

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

A retrospective analysis of ezetimibe treatment in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02272.X

10.1111/J.1600-6143.2008.02272.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference